Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

206.36
-1.5200-0.73%
Volume:1.06M
Turnover:215.21M
Market Cap:44.23B
PE:-23.13
High:206.54
Open:205.01
Low:200.53
Close:207.88
52wk High:224.31
52wk Low:37.88
Shares:214.34M
Float Shares:184.00M
Volume Ratio:0.45
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:16.97
PE(LYR):-34.68

Loading ...

Revolution Medicines, Inc. : Bernstein Raises Target Price to $179 from $151

THOMSON REUTERS
·
Aug 21

Revolution Medicines Advances RASolve 308 Lung Cancer Trial, Raising Long-Term Upside Potential for RVMD

TIPRANKS
·
Aug 21

Movement Alert|Revolution Medicines, Inc. Rises 5.05% in Regular Trading, BeiGene RAS Inhibitor Collaboration Continues to Drive Momentum

Market Focus
·
Aug 18

Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal

Reuters
·
Aug 13

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

GlobeNewswire
·
Aug 12

Revolution Medicines Price Target Raised to $231.00/Share from $210.00 by Truist Securities

Dow Jones
·
Aug 12

U.S. Stocks on the MOVEX-Abbott, Columbia Financial, Jabil,

Reuters
·
Aug 11

Tango Falls After Wider-than-Expected Quarterly Loss

Reuters
·
Aug 11

U.S. Stocks on the MOVE-Duke Energy, Sea, Cardinal Health

Reuters
·
Aug 11

Truist Raises Revolution Medicines PT on Lung Cancer Pipeline Potential

Reuters
·
Aug 11

BEONE MEDICINES Surges Over 4% in Morning Trading on Strategic Partnership with Revolution Medicines to Accelerate RAS Drug Development

Stock News
·
Aug 11

Analysts’ Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)

TIPRANKS
·
Aug 10

BeOne Medicines partners with Revolution Medicines for clinical development

TIPRANKS
·
Aug 10

BeOne Medicines Teams with Revolution Medicines on RAS Cancer Drug Development, Asia Rights Deal

Reuters
·
Aug 10

Beone Medicines - Receives Exclusive Rights to Four Revolution Medicines Assets in Select Asian Markets

THOMSON REUTERS
·
Aug 10

Beone Medicines - to Fund and Conduct Global Phase 3 Study for Ras(on) Inhibitor

THOMSON REUTERS
·
Aug 10

Beone Medicines - Revolution Medicines Eligible for Milestone Payments and Tiered Royalties in Partnered Region

THOMSON REUTERS
·
Aug 10

Revolution Medicines, Inc. : JP Morgan Raises Target Price to $227 from $205

THOMSON REUTERS
·
Aug 10

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)

TIPRANKS
·
Aug 08

Revolution Medicines price target raised to $227 from $205 at JPMorgan

TIPRANKS
·
Aug 08